Roger Dmochowski led the peer-review process as the Associate Editor responsible for the paper.
Original Clinical Article
Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people >65 years of age: A post hoc analysis of data from the SOFIA study
Article first published online: 3 APR 2014
© 2014 Wiley Periodicals, Inc.
Neurourology and Urodynamics
How to Cite
Wagg, A., Darekar, A., Arumi, D., Khullar, V. and Oelke, M. (2014), Factors associated with dose escalation of fesoterodine for treatment of overactive bladder in people >65 years of age: A post hoc analysis of data from the SOFIA study. Neurourol. Urodyn.. doi: 10.1002/nau.22603
Conflict of interest: A. Wagg has Received industry support for either research, speaker honoraria or consultancy from Astellas Pharma, Pfizer Ltd, PRMA Consulting (UK), SCA and Watson Pharma. A. Darekar and D. Arumi are employees of Pfizer Ltd. V. Khullar has Received industry support for either research, speaker honoraria or consultancy from Astellas Pharma, Pfizer Ltd, Takeda and Allergan M. Oelke has Received industry for either research, speaker honoraria or consultancy from Allergan, Apogepha, Astellas, Ferring, GlaxoSmithKline, Lilly, Pfizer, Recordati and Sophiris.
- Article first published online: 3 APR 2014
- Manuscript Accepted: 10 MAR 2014
- Manuscript Received: 4 DEC 2013
- health services;
- overactive bladder
To investigate factors which may influence dose escalation of antimuscarinics for overactive bladder (OAB) in older patients and how dose escalation affects treatment efficacy.
Materials and Methods
A post hoc analysis of data from the 12-week randomized, placebo controlled phase of the SOFIA study investigating treatment with fesoterodine in older people with OAB. Predictors and outcomes in patients aged ≥65 years with OAB who did or did not choose to escalate from fesoterodine 4 to 8 mg before the first dose-escalation choice point (week 4) and at the end of the study (week 12) were assessed.
Variables which significantly increased likelihood of dose escalation were, at baseline, body mass index (OR: 1.06, 95% CI 1.01, 1.12; P = 0.0222), and male gender (OR: 2.06, 95% CI 1.28, 3.32; P = 0.0028) and at week 4, change from baseline in urgency episodes (OR: 1.12, 95% CI 1.05, 1.20; P = 0.0008), patient perception of bladder control (PPBC) (OR: 1.44, 95% CI 1.12, 1.84; P = 0.004). At week 12, dose escalation was associated with slightly reduced treatment outcomes compared to week 4 non-escalators.
No baseline disease related factor associated with dose escalation was identified. Magnitude of change in urgency episodes and reduction in PPBC at 4 weeks were associated with dose escalation. These data may be of use to healthcare providers as they allow judgement to be made in individual patients, allowing treatment decisions to be made. At end of treatment, improvements in efficacy and quality of life were achieved in both escalators and non-escalators. Neurourol. Urodynam. © 2014 Wiley Periodicals, Inc.